CorMedix Inc.
HealthcareNASDAQ:CRMD · NASDAQ Global Market
-$0.22 today
Vol 0.97M · Avg 1.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
40.2%
avg -31.1%
ROIC
23.0%
avg -108.6%
ROA
19.7%
avg -71.9%
Analysis
ROE is currently the strongest return metric at 40.2% versus its period average of -31.1%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph Todisco | CEO & Chairman of the Board of Directors | $1.61M | — | 50 | $774,749.00 | 0.99% |
Kaufman Beth Zelnick | EVP, Chief Legal and Compliance Officer & Corporate Secretary | $981,592.00 | — | 65 | $269,108.00 | 0.34% |
Elizabeth Hurlburt | Executive Vice President, Chief Operating Officer & Chief Integration Officer | $959,370.00 | — | 47 | $278,539.00 | 0.36% |
Matthew T. David | EVP & Chief Business Officer | $634,855.00 | — | 48 | $0.00 | <0.01% |
Susan Blum | Executive Vice President & Chief Financial Officer | $634,855.00 | — | 53 | $142,506.00 | 0.18% |
Michael Seckler | Executive Vice President & Chief Commercial Officer | $561,571.00 | — | 60 | $0.00 | <0.01% |
Donna Ucci | Senior Vice President & Head of Global Quality | — | — | — | — | — |
Peter Sullivan BCOP | Senior Vice President of Market Access | — | — | — | — | — |
Tushar Mukherjee | Senior Vice President & Head of Technical Operations | — | — | — | — | — |
Jared L. Crandon | Executive Director of Clinical Portfolio Management | — | — | — | $140,000.00 | 0.18% |
Beth Steinbrenner | SVP & Chief Human Resource Officer | — | — | — | $269,108.00 | 0.34% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$275,500.00
Sells
14
$4.81M
Net Sentiment
$4.53M
Net selling
Most Active
Dillione Janet
5 transactions
1–10 of 15
Analysis
Insiders reported 1 buys worth $275,500.00 and 14 sells worth $4.81M over the last 12 months. That adds up to net selling of $4.53M. Dillione Janet was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +68.2% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +68.2% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$1.29B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages CRMD?
CorMedix Inc. (CRMD) lists 11 active executives. The top listed executive is Elizabeth Hurlburt, Executive Vice President, Chief Operating Officer & Chief Integration Officer.
Are CRMD insiders buying or selling?
Recent insider activity shows net selling of $3.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.